Dimensional Fund Advisors LP Boosts Stake in OptimizeRx Co. (NASDAQ:OPRX)

Dimensional Fund Advisors LP increased its holdings in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 9.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 444,167 shares of the company's stock after acquiring an additional 39,740 shares during the quarter. Dimensional Fund Advisors LP owned about 2.41% of OptimizeRx worth $2,159,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in OPRX. Barclays PLC increased its holdings in shares of OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company's stock worth $208,000 after acquiring an additional 21,060 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of OptimizeRx during the 4th quarter worth approximately $51,000. Greenwood Capital Associates LLC grew its holdings in OptimizeRx by 31.5% in the 4th quarter. Greenwood Capital Associates LLC now owns 88,596 shares of the company's stock valued at $431,000 after buying an additional 21,240 shares in the last quarter. AMH Equity Ltd grew its holdings in OptimizeRx by 25.0% in the 4th quarter. AMH Equity Ltd now owns 125,000 shares of the company's stock valued at $608,000 after buying an additional 25,000 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in OptimizeRx in the 4th quarter valued at $25,000. 76.47% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director James Paul Lang purchased 321,408 shares of OptimizeRx stock in a transaction dated Friday, March 14th. The stock was bought at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the transaction, the director now owns 389,452 shares in the company, valued at $2,959,835.20. This trade represents a 472.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 5.60% of the stock is owned by company insiders.

OptimizeRx Stock Performance

Shares of OPRX traded down $0.18 during mid-day trading on Tuesday, hitting $12.03. The stock had a trading volume of 14,052 shares, compared to its average volume of 276,568. The firm has a market cap of $222.40 million, a P/E ratio of -9.14 and a beta of 1.28. The business has a fifty day moving average price of $8.85 and a 200-day moving average price of $6.54. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23. OptimizeRx Co. has a 52 week low of $3.78 and a 52 week high of $13.33.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.19. The company had revenue of $21.93 million during the quarter, compared to analysts' expectations of $18.69 million. OptimizeRx had a negative return on equity of 4.92% and a negative net margin of 27.41%. On average, equities research analysts expect that OptimizeRx Co. will post -0.33 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have commented on OPRX. Stifel Nicolaus upped their price objective on OptimizeRx from $8.00 to $12.50 and gave the company a "buy" rating in a report on Tuesday, May 13th. JMP Securities upped their price objective on OptimizeRx from $11.00 to $14.00 and gave the stock a "market outperform" rating in a research report on Tuesday, May 13th. B. Riley restated a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Roth Capital reaffirmed a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Finally, Citigroup reissued an "outperform" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $10.38.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.